Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14902500 | 0.93 | NPC1 (0.58) | NPC1SIGMAR1ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL14905956 | 0.88 | NPC1 (0.54) | NPC1SIGMAR1ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL14932739 | 0.87 | NPC1 (0.53) | NPC1SIGMAR1ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL14902533 | 0.87 | NPC1 (0.53) | NPC1SIGMAR1ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL14902494 | 0.84 | NPC1 (0.54) | NPC1SIGMAR1ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL28089189 | 0.82 | NPC1 (0.52) | NPC1SIGMAR1ALDH1A1TDP1MEN1 | |
| SCHEMBL14902534 | 0.82 | NPC1 (0.51) | NPC1SIGMAR1ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL14902498 | 0.82 | NPC1 (0.51) | NPC1SIGMAR1ALDH1A1TDP1MEN1 | |
| SCHEMBL14902532 | 0.82 | NPC1 (0.51) | NPC1SIGMAR1ALDH1A1TDP1MEN1 | |
| SCHEMBL14902486 | 0.81 | NPC1 (0.51) | NPC1SIGMAR1ALDH1A1TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109697-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109697-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | SCNN1B, SCNN1A, TRPM5 | NPC1 976/4885SIGMAR1 2217/4885ALDH1A1 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.